A detailed history of Silverarc Capital Management, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Silverarc Capital Management, LLC holds 146,657 shares of PTGX stock, worth $5.96 Million. This represents 1.64% of its overall portfolio holdings.

Number of Shares
146,657
Holding current value
$5.96 Million
% of portfolio
1.64%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$33.72 - $47.33 $4.95 Million - $6.94 Million
146,657 New
146,657 $6.59 Million
Q2 2023

Aug 14, 2023

SELL
$18.02 - $29.36 $1.45 Million - $2.36 Million
-80,486 Reduced 76.3%
25,000 $690,000
Q1 2023

May 15, 2023

BUY
$10.78 - $25.38 $1.14 Million - $2.68 Million
105,486 New
105,486 $2.43 Million
Q1 2021

May 18, 2021

SELL
$19.02 - $31.15 $397,708 - $651,346
-20,910 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$18.49 - $25.13 $386,625 - $525,468
20,910 New
20,910 $422,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Silverarc Capital Management, LLC Portfolio

Follow Silverarc Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverarc Capital Management, LLC with notifications on news.